Interleukin-1α as a Potential Prognostic Biomarker in Pancreatic Cancer.

Purpose: We assessed the prognostic role of pro-inflammatory cytokines of the IL-1 superfamily in patients with pancreatic cancer.

Methods: This retrospective study was performed using two independent cohorts of patients with pancreatic cancer: the International Cancer Genome Consortium (ICGC, N = 267) cohort and The Cancer Genome Atlas (TCGA, N = 178) cohort. Univariate Cox regressions were used to identify prognosis-related pro-inflammatory cytokines of the IL-1 superfamily. Cytokines associated with outcome were included in a multivariate Cox model with relevant clinicopathological variables to identify prognostic biomarkers.

Results: IL-1α was the only pro-inflammatory cytokine of the IL-1 superfamily that was significantly associated with prognosis in both cohorts. In the training cohort (ICGC), the decile of patients with the lowest expression had better overall survival (HR = 1.99 [1.01-3.93], = 0.05) and better relapse-free survival (HR = 1.85 [1.02-3.34], = 0.04) than the group with the highest expression. The validation cohort (TCGA) confirmed these results: the decile with the lowest expression had better overall survival (HR = 3.00 [1.14-7.90], = 0.03) and a lower risk of progression (HR = 3.11 [1.24-7.80], = 0.01).

Conclusions: is an independent prognostic marker and could be considered a potential therapeutic target in pancreatic cancer patients.